Your Gift Drives Research

Exciting Results in Trial for Grade 2 Oligodendroglioma and Astrocytoma Patients Today, at the American Society for Clinical Oncology Annual Meeting positive results were presented from a large, international phase III clinical trial (INDIGO trial) of patients older than 12 with grade 2 IDH-mutated diffuse glioma. The results were also published simultaneously in the New England Journal of Medicine. The trial evaluated whether a drug called […] June 5, 2023

World Class Hospitals Join DNA Damage Response Consortium to Bring Forward New Treatments for Adults and Children with Brain Cancer Researchers from St. Jude Children’s Research Hospital, NYU, UCSF, and the University of Minnesota join National Brain Tumor Society and Yale-led Initiative   Today, the National Brain Tumor Society (NBTS), in partnership with Yale Cancer Center, announced new partners for its DNA Damage Response Consortium. Joining the initiative are world-class experts in adult and pediatric neuro-oncology […] March 28, 2023

New Approval of Treatment for Young Children with Certain Brain Cancers On March 16, 2023, the U.S. Food and Drug Administration approved a new treatment combination that will now be available as an option for pediatric patients 1 year of age and older with low-grade glioma (LGG, grade 1 or 2) that have a mutation called BRAF V600E. This marks the first FDA approval of a […] March 21, 2023

[White Paper] Assessing Uptake of Remote Consent for Clinical Trials: Opportunities to Reduce Patient Burden A white paper from the National Brain Tumor Society and the LUNGevity Foundation Executive Summary While the COVID-19 public health emergency has caused major disruption to many clinical studies, one positive outgrowth has been the opportunity afforded trials sponsors, investigators, and regulators to implement elements of decentralized trials in on-going clinical studies. Decentralized clinical trials […] January 18, 2023

Guest Blog: A Patient and Philosopher Goes to the Biggest Brain Tumor Research Conference of the Year Glioblastoma patient and NBTS Board member, Adam Hayden, reflects on attending the 2022 Society for Neuro-Oncology Annual Meeting The Philosopher-Patient I was diagnosed with glioblastoma in the final year of my graduate studies, ironically specializing in the Philosophy of Science. Ironic because what could be more absurd than a philosopher with brain cancer?! The brain […] December 16, 2022